规格 | 价格 | |
---|---|---|
500mg | ||
1g | ||
Other Sizes |
靶点 |
Succinate dehydrogenase
|
---|---|
体内研究 (In Vivo) |
Bixafen(BIX)是琥珀酸脱氢酶抑制剂(SDHI)类杀菌剂中的一员,由于其不断扩大的市场份额和积极的发展前景,人们对它的兴趣激增。然而,人们越来越担心它对水生生物的潜在危害,这主要是由于它在环境中不易分解。在这项研究中,我们深入研究了BIX作为模型生物对斑马鱼的毒理学影响。我们的研究结果表明,BIX显著阻碍了斑马鱼胚胎的发育,导致死亡率增加、孵化失败和氧化应激。此外,我们观察到心血管异常,包括心腔扩张、心率减慢、血液循环迟缓和血管功能受损。值得注意的是,BIX还改变了参与心血管发育的关键基因的表达,如myl7、vmhc、nkx2.5、tbx5和flt1。总之,BIX被发现会诱导斑马鱼的发育和心血管毒性,强调了与SDHI农药相关的风险,并强调了重新评估其对人类健康影响的必要性。这些发现对于负责任地使用BIX至关重要[1]。
|
动物实验 |
Bixafen exposure [1]
Following the Organization for Economic Co-operation and Development (OECD) test guideline No. 236, zebrafish embryos were exposed to a range of BIX concentrations (0.05, 0.1, 0.2, 0.4, and 0.8 μM) to evaluate their survival rates (OECD, 2013). Each treatment group contained 30 post-fertilized eggs in 10 mL of solution within Petri dishes. The DMSO solution at the same concentration served as the solvent control. Embryos were exposed to various BIX concentrations for 72 h post-fertilization (hpf). To ensure a constant BIX concentration, the solution was replaced every 24 h. Each treatment group was replicated three times to confirm reproducibility. The highest concentration of BIX that did not result in significant embryonic lethality by 72hpf was designated as the exposure concentration. Survival rates were measured at 24, 48, and 72 hpf, while hatching rates were noted at 48 and 72 hpf. Furthermore, measurements of eye length, trunk pigmentation area, body length, and deformity rates were conducted at 72 hpf, and the observation of autonomous movement was made at 24 hpf. |
毒性/毒理 (Toxicokinetics/TK) |
RAIS Toxicity Values
Oral Acute Reference Dose (RfDoa)(mg/kg-day) 2.5 Oral Acute Reference Dose Reference OPP Oral Chronic Reference Dose (RfDoc) (mg/kg-day) 0.03 Oral Chronic Reference Dose Reference OPP |
参考文献 |
[1]. Insights into the developmental and cardiovascular toxicity of bixafen using zebrafish embryos and larvae. Environ Res. 2024 Dec 1;262(Pt 2):119916.
|
其他信息 |
Bixafen is an aromatic amide obtained by formal condensation of the carboxy group of 3-(difluoromethyl)-1-methylpyrazole-4-carboxylic acid with the amino group of 3',4'-dichloro-5-fluorobiphenyl-2-amine. A fungicide for use in cereals for key stem and leaf disease control including strobilurin-resistant septoria. It has a role as an EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor and an antifungal agrochemical. It is an aromatic amide, an organofluorine compound, a member of pyrazoles, a member of biphenyls, a dichlorobenzene and an anilide fungicide.
|
分子式 |
C18H12N3OF3CL2
|
---|---|
分子量 |
414.20858
|
精确质量 |
413.031
|
元素分析 |
C, 52.20; H, 2.92; Cl, 17.12; F, 13.76; N, 10.14; O, 3.86
|
CAS号 |
581809-46-3
|
PubChem CID |
11434448
|
外观&性状 |
Typically exists as solid at room temperature
|
沸点 |
474.653 ℃ at 760mmHg
|
熔点 |
146 ℃
|
闪点 |
240.862 ℃
|
LogP |
6.106
|
tPSA |
50.41
|
氢键供体(HBD)数目 |
1
|
氢键受体(HBA)数目 |
5
|
可旋转键数目(RBC) |
4
|
重原子数目 |
27
|
分子复杂度/Complexity |
530
|
定义原子立体中心数目 |
0
|
SMILES |
CN1C=C(C(NC2=C(C3=CC(Cl)=C(Cl)C=C3)C=C(F)C=C2)=O)C(C(F)F)=N1
|
InChi Key |
LDLMOOXUCMHBMZ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H12Cl2F3N3O/c1-26-8-12(16(25-26)17(22)23)18(27)24-15-5-3-10(21)7-11(15)9-2-4-13(19)14(20)6-9/h2-8,17H,1H3,(H,24,27)
|
化学名 |
N-[2-(3,4-dichlorophenyl)-4-fluorophenyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide
|
别名 |
Bixafen; 581809-46-3; Bixafen [ISO]; bixafene; UNII-28XK2L8M3B; 28XK2L8M3B; AVIATOR XPRO; BOOGIE XPRO;
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
溶解度 (体内实验) |
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。 注射用配方 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4142 mL | 12.0712 mL | 24.1423 mL | |
5 mM | 0.4828 mL | 2.4142 mL | 4.8285 mL | |
10 mM | 0.2414 mL | 1.2071 mL | 2.4142 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。